Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Chris Blumas and The Panic-Proof Portfolio (Stockchase Research) commented about whether BIIB-Q, CIEN-N, ETSY-Q, HAS-Q, APPS-Q, ENGH-T, AX.UN-T, ABT-N, SJR.B-T, AAPL-Q, BAM.A-T, COST-Q, DLTR-Q, AQN-T, GIB.A-T, DLTR-Q, IFP-T, T-N, NTR-T, BBD.B-T, SU-T are stocks to buy or sell.
- Page 2/2
- Next Page
TOP PICK
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
biotechnology
pharmaceutical
TOP PICK
It's exposed to western Canada, an unloved asset class, but the valuation is very attractive and the new CEO has a new plan to flexibly invest in private and public real estate. This combination is great. The dividend pays over 5%, so you're paid to wait. The CEO has a track record restructuring asset. Artis trades at a 25% discount to NAV.
property mngmnt
investment
TOP PICK
Most revenues come outside Canada. They've done a fine job consolidating companies over the years. Covid has slowed these deals, so Q1 organic growth was negative. They report this week, and organic growth is expected to remain negative. However, they saw a big bump in videoconferencing sales. Long term, their growth profile is strong. The valuation is near its historic lows and a discount to peers. (Analysts’ price target is $74.25)
computer software
processing
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly The e-commerce company and app developer has been a poster child of tech sector during the pandemic. It has ridden the highs and has now retraced to a level of reasonable value. Revenue is up 142% and EPS of $0.25 comfortably beat analyst calls for $0.19. They continue to add to the cash reserves. Revenue growth is expected to remain strong putting forward PE in a more respectable 32x. We would buy this with a stop loss at $55, looking to achieve $103 -- upside potential over 39%. Yield 0% (Analysts’ price target is $103.20)
Technology
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly HAS is planning to capitalize on its G.I. Joe brand with a soon to be released movie and grow its other entertainment and game franchises. Recent EPS of $1.00 beat analyst's calls for $0.68. It has a strong cash holdings over $1.4 billion, even after paying down $300 million in debt. It pays a decent dividend backed by a payout ratio under 75% of cashflow. We would buy this with a stop loss at $85, looking to achieve $111 -- upside potential over 15%. Yield 2.87% (Analysts’ price target is $110.71)
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly This e-commerce company has been around a while. The pandemic allowed its platform to grow substantially. Earnings growth is expected to exceed 45% for the next five years, which makes the current 44x earnings, pretty decent value. We would buy this with a stop loss at $140, looking to achieve $226 -- upside over 32%. Yield 0% (Analysts’ price target is $226.13)
Technology
Premium content
PAST TOP PICK
(A Top Pick May 04/21, Up 18.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has achieved its $60 target. To be disciplined, we recommend covering 50% of the holding and trailing up the stop (from $39) to $51. If triggered, this would all but guarantee a minimum investment return over 9%.
misc industrial products
Premium content
PAST TOP PICK
(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.
biotechnology
pharmaceutical
PARTIAL BUY
Allan Tong’s Discover Picks As a stock, where does Cineplex lie? Common metrics won’t work with CGX stock. For starters, YOY comps don’t exist. Meanwhile, the Cineworld lawsuit is a cloud. In the past week, Cineplex has probably enjoyed some momentum from the AMC euphoria and has climbed about $1 to $16.15 (Monday’s close). Right before the pandemic, Cineplex was trading above $33, though well off its 2017 peak of around $53. The street has three holds and one buy at a price target of $13.13, or almost 18% downside. I disagree. I see a little more upside here. CGX stock is an unscientific gut feeling call as a cautious, partial buy. Read 3 Hot TSX Stocks for our full analysis.
other services
BUY
Allan Tong’s Discover Picks NTR stocks are currently hitting all-time highs right below $80. There’s a little more upside that the street sees with a price target of $80.67, though I predict the low-$80s is more likely. Cyclical stocks are trades, not long-term holds, so there’s wiggle room to earn a 5-8% return if you’re nimble. Of course, buying on dip is a good idea, but a dip is less likely on a name with such momentum. NTR stocks are up nearly 8% in the past month. Bottom line: be nimble, Jack. Read 3 Hot TSX Stocks for our full analysis.
agriculture
BUY
Allan Tong’s Discover Picks After years of ups and downs, Savaria turned a corner last winter when it bought Handicare to double the company’s size and become the global market leader. Of course, the underlying tailwind remains aging demographics. It’s a lot cheaper for a senior to install an elevator in their home than to move into a residence. Also, how Covid ravaged nursing homes in 2020 is tragically fresh on everyone’s minds. Savaria’s last four quarters actually saw two beats and two misses in earnings, so the street is betting on the future. For example, SIS stock’s EPS estimate for Q4 2021 is 22 cents compared to the actual 13 cents of Q4 2020. There’s still upside here, so this is definitely a buy. Read 3 Hot TSX Stocks for our full analysis.
other services
